Full-Time

Associate Director

Commercial Analytics & Forecasting

Confirmed live in the last 24 hours

Axsome Therapeutics Inc

Axsome Therapeutics Inc

201-500 employees

Develops therapies for CNS disorders

Compensation Overview

$145k - $175k/yr

+ Bonus + Equity

Senior

New York, NY, USA

In Person

On-site requirement of at least three days per week; unable to consider candidates looking for fully remote roles.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Python
R
SQL
Requirements
  • Bachelor’s degree in a quantitative field (Engineering, Math, Physics, Statistics, Computer Science or, Operations Research) is required; Master's/PhD degree is preferred
  • Minimum 7 years of pharmaceutical marketing analytics experience
  • Demonstrated hands on experience with programming languages (Python, R, SQL) and analytics platforms
  • Extensive knowledge of secondary and syndicates data sources
  • Exceptional communication skills, including strong presentation ability
  • Ability to work on site Monday, Tuesday & Thursday
Responsibilities
  • Develop and maintain performance trackers while conducting comprehensive analytics for the commercial teams, providing insights to guide strategic and forecasting initiatives
  • Perform subnational analysis to advocate for local insights, identifying growth opportunities through descriptive, prescriptive, and predictive analytics
  • Design and implement segmentation models to uncover potential growth areas; derive insights on market mapping and patient journeys, leveraging PTD and EMR datasets
  • Provide essential ad-hoc analytics for integrated and quarterly business reviews, collaborating closely with internal teams, including market research, data strategy, and commercial operations
  • Conduct demand forecasting initiatives using diverse methodologies and develop patient flow models for product valuation in collaboration with other stakeholders
  • Manage multiple analytics projects simultaneously, ensuring high-quality standards and adherence to critical deadlines
Desired Qualifications
  • Proven experience working with pharmaceutical data sources including patient claims data (IQVIA/SHA), sales force activity data, and real-world evidence data (MarketScan, Optum claims)
  • Proficiency with programming languages (Python, R, SQL)
  • Proficiency in data visualization tools and CRM systems (Salesforce, Veeva)
  • Strong background in statistical analysis and predictive modeling
  • Excellent communication skills with the ability to present complex analysis to various stakeholders
  • CNS therapeutic knowledge preferred, but not required
Axsome Therapeutics Inc

Axsome Therapeutics Inc

View

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, agitation from Alzheimer's disease, migraine, narcolepsy, fibromyalgia, and smoking cessation. Their main product, AXS-05, is an oral medication that acts as an NMDA receptor antagonist to help regulate mood. It has shown positive results in clinical trials and has received FDA Breakthrough Therapy Designation, which speeds up its development process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous clinical trials and regulatory approvals. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients.

Company Size

201-500

Company Stage

IPO

Headquarters

New York City, New York

Founded

2012

Simplify Jobs

Simplify's Take

What believers are saying

  • Axsome's expansion in NYC supports growth and operational capacity by December 2025.
  • $570 million credit facility with Blackstone strengthens financial stability and flexibility.
  • Positive Phase 3 results for AXS-05 and AXS-12 boost market confidence.

What critics are saying

  • Increased competition from Sage Therapeutics and Biogen in CNS disorder treatments.
  • Potential regulatory delays could impact drug approval timelines and market entry.
  • Financial strain from NYC expansion could affect resource allocation and operations.

What makes Axsome Therapeutics Inc unique

  • Axsome focuses on CNS disorders, addressing unmet medical needs in this area.
  • AXS-05, an NMDA receptor antagonist, is a flagship product for depression treatment.
  • FDA Breakthrough Therapy Designation expedites AXS-05's development and review process.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company Equity

Company News

EMPR
Jun 10th, 2025
Symbravo Now Available for the Acute Treatment of Migraine

Axsome Therapeutics announces availability of Symbravo(R) (meloxicam and rizatriptan) for the acute treatment of migraine with or without aura in adults.

Intelligence360
Jun 3rd, 2025
Axsome Therapeutics Plans 96,000 Sq.Ft. Expansion In New York City.

Axsome Therapeutics plans 96,000 Sq.Ft. expansion in New York City. Axsome Therapeutics plans 96,000 Sq.Ft. expansion in New York City.New York, New York — According to state and local development sources, Axsome Therapeutics plans to build out 96,000 square feet of new space in New York. The company plans to occupy the new space in New York, on or about December 1, 2025. According to the company website Axsome Therapeutics, Inc

Stock Titan
May 13th, 2025
Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone

Axsome Therapeutics (NASDAQ: AXSM) has secured a $570 million term loan and revolving credit facility with Blackstone, replacing its previous Hercules Capital term loan. The facility consists of a $500 million term loan and a $70 million revolving credit facility. The company initially drew $120 million to retire its previous loan.The new facility offers improved terms, including interest rates of SOFR plus 4.75% for the term loan and SOFR plus 4.0% for the revolving credit facility, with a 60-month interest-only period and maturity in May 2030. Additionally, Blackstone purchased $15 million of Axsome common stock at $107.14 per share. The company can access an additional $250 million at its option, with another $200 million available subject to Blackstone's approval.

Life Care News
May 1st, 2025
Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month

NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) - Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it is joining with Mental Health America (MHA) and the broader mental health advocacy community in a consolidated effort to raise awareness and promote action during May's Mental Health Month.

Clival
Apr 8th, 2025
Axsome to Present Positive Phase 3 AXS-05 & AXS-12 Results at AAN 2025

Axsome Therapeutics, Inc., a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, announced multiple presentations spanning its innovative, industry-leading psychiatry and neurology portfolio at the 2025 American Academy of Neurology (AAN) Annual Meeting, being held April 5-9 in San Diego, California.